The University of Chicago Header Logo

Connection

Julie Fitzgerald to Drug Resistance, Neoplasm

This is a "connection" page, showing publications Julie Fitzgerald has written about Drug Resistance, Neoplasm.
Connection Strength

0.150
  1. Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial. J Clin Oncol. 2021 03 10; 39(8):920-930.
    View in: PubMed
    Score: 0.150
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.